Covid-19大流行对北注册制药公司绩效的影响

Iriana Kusuma Dewi, Putri Nilam Kencana
{"title":"Covid-19大流行对北注册制药公司绩效的影响","authors":"Iriana Kusuma Dewi, Putri Nilam Kencana","doi":"10.33753/madani.v5i1.197","DOIUrl":null,"url":null,"abstract":"The purpose of the study was to see differences in financial performance before and when the covid-19 virus was first announced in Indonesia, in pharmaceutical companies listed on the IDX. The analytical method used is the Paired Sample T-Test Difference. The population in this study were all pharmaceutical companies listed on the Indonesia Stock Exchange as many as 12 companies. The sample used in this study were 11 companies in the 2019-2021 period consisting of Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (BRAND), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Sido Muncul Herbal and Pharmaceutical Industry Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), and Millennium Pharmacon International Tbk (SDPC). The results of the study found that there were no differences in financial performance before and during the covid-19 virus in pharmaceutical companies listed on the IDX in terms of liquidity ratios, activity ratios, and profitability ratios. Based on the results of the study, it can be concluded that there is no difference in financial performance before and during the covid-19 pandemic. \nAbstrak \nTujuan Penelitian untuk melihat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pertama kali di umumkan di Indonesia, pada perusahaan Farmasi yang terdaftar di BEI. Metode analisis yang digunakan adalah Uji Beda Paired Sample T-Test. Populasi dalam penelitian ini adalah seluruh perusahaan Farmasi yang terdaftar di Bursa Efek Indonesia yakni sebanyak 12 Perusahaan. Sampel yang digunakan dalam penelitian ini adalah 11 perusahaan pada periode 2019-2021 yang terdiri dari Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (MERK), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Industri Jamu Dan Farmasi Sido Muncul Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), dan Millennium Pharmacon International Tbk (SDPC). Hasil Penelitian menemukan bahwa tidak terdapat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pada perusahaan farmasi yang terdaftar di BEI ditinjau dari rasio likuiditas, rasio aktivitas, dan rasio profitabilitas. Berdasarkan hasil penelitian maka dapat disimpulkan tidak terdapat perbedaan kinerja keuangan sebelum dan saat pandemi virus covid-19. \nKata Kunci: Likuiditas, Aktivitas, Profitabilitas, Kinerja Keuangan   ","PeriodicalId":205542,"journal":{"name":"Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Dampak Pandemi Covid-19 Terhadap Kinerja Perusahaan Farmasi yang terdaftar di BEI\",\"authors\":\"Iriana Kusuma Dewi, Putri Nilam Kencana\",\"doi\":\"10.33753/madani.v5i1.197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose of the study was to see differences in financial performance before and when the covid-19 virus was first announced in Indonesia, in pharmaceutical companies listed on the IDX. The analytical method used is the Paired Sample T-Test Difference. The population in this study were all pharmaceutical companies listed on the Indonesia Stock Exchange as many as 12 companies. The sample used in this study were 11 companies in the 2019-2021 period consisting of Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (BRAND), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Sido Muncul Herbal and Pharmaceutical Industry Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), and Millennium Pharmacon International Tbk (SDPC). The results of the study found that there were no differences in financial performance before and during the covid-19 virus in pharmaceutical companies listed on the IDX in terms of liquidity ratios, activity ratios, and profitability ratios. Based on the results of the study, it can be concluded that there is no difference in financial performance before and during the covid-19 pandemic. \\nAbstrak \\nTujuan Penelitian untuk melihat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pertama kali di umumkan di Indonesia, pada perusahaan Farmasi yang terdaftar di BEI. Metode analisis yang digunakan adalah Uji Beda Paired Sample T-Test. Populasi dalam penelitian ini adalah seluruh perusahaan Farmasi yang terdaftar di Bursa Efek Indonesia yakni sebanyak 12 Perusahaan. Sampel yang digunakan dalam penelitian ini adalah 11 perusahaan pada periode 2019-2021 yang terdiri dari Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (MERK), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Industri Jamu Dan Farmasi Sido Muncul Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), dan Millennium Pharmacon International Tbk (SDPC). Hasil Penelitian menemukan bahwa tidak terdapat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pada perusahaan farmasi yang terdaftar di BEI ditinjau dari rasio likuiditas, rasio aktivitas, dan rasio profitabilitas. Berdasarkan hasil penelitian maka dapat disimpulkan tidak terdapat perbedaan kinerja keuangan sebelum dan saat pandemi virus covid-19. \\nKata Kunci: Likuiditas, Aktivitas, Profitabilitas, Kinerja Keuangan   \",\"PeriodicalId\":205542,\"journal\":{\"name\":\"Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora\",\"volume\":\"28 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33753/madani.v5i1.197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33753/madani.v5i1.197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

这项研究的目的是观察在印尼IDX上市的制药公司在covid-19病毒首次在印度尼西亚宣布之前和之后的财务表现差异。使用的分析方法是配对样本t检验差异。本研究的人群均为在印尼证券交易所上市的制药公司,多达12家。本研究使用的样本是2019-2021年期间的11家公司,包括Darya-Varia laboratories Tbk (DVLA)、Indofarma Tbk (INAF)、PT Kimia Farma Tbk (KAEF)、Kalbe Farma Tbk (KLBF)、Merck Tbk (BRAND)、PT Phapros Tbk (PEHA)、Pyridam Farma Tbk (PYFA)、PT Organon Pharma Indonesia Tbk (SCPI)、PT Sido Muncul Herbal and Pharmaceutical Industry Tbk (Sido)、Tempo Scan Pacific Tbk (TSPC)和Millennium Pharmacon International Tbk (SDPC)。研究结果发现,在IDX上市的制药公司在covid-19病毒之前和期间的财务业绩在流动性比率,活动比率和盈利比率方面没有差异。根据研究结果,可以得出结论,在covid-19大流行之前和期间,财务绩效没有差异。摘要/ abstract摘要/ abstract摘要/ abstract摘要/ abstract摘要:图juan Penelitian untutuk meltik -1病毒(covid-19)在印度尼西亚的流行性腮腺炎(perperama kali di umumkan),在印度尼西亚的流行性腮腺炎(perperusaan)和Farmasi yang的数据。方法分析:yang digunakan adalah Uji Beda配对样本t检验。Populasi dalam penelitian ini adalah seluruh perusahaan Farmasi yang terdattar di Bursa Efek印度尼西亚yakni sebanyak 12 perusahaan。yang terdiri dari Darya-Varia laboratories Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF),默克公司(MERK), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Industri Jamu Dan Farmasi Sido Muncul Tbk (Sido), Tempo Scan Pacific Tbk (TSPC), Dan Millennium Pharmacon International Tbk (SDPC)。哈希尔·佩尼利特(Hasil Penelitian)的menemukan - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha - haha。在新冠肺炎大流行之前,我们要先做好防疫准备,做好防疫准备。Kata Kunci: Likuiditas, Aktivitas, Profitabilitas, Kinerja Keuangan
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dampak Pandemi Covid-19 Terhadap Kinerja Perusahaan Farmasi yang terdaftar di BEI
The purpose of the study was to see differences in financial performance before and when the covid-19 virus was first announced in Indonesia, in pharmaceutical companies listed on the IDX. The analytical method used is the Paired Sample T-Test Difference. The population in this study were all pharmaceutical companies listed on the Indonesia Stock Exchange as many as 12 companies. The sample used in this study were 11 companies in the 2019-2021 period consisting of Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (BRAND), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Sido Muncul Herbal and Pharmaceutical Industry Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), and Millennium Pharmacon International Tbk (SDPC). The results of the study found that there were no differences in financial performance before and during the covid-19 virus in pharmaceutical companies listed on the IDX in terms of liquidity ratios, activity ratios, and profitability ratios. Based on the results of the study, it can be concluded that there is no difference in financial performance before and during the covid-19 pandemic. Abstrak Tujuan Penelitian untuk melihat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pertama kali di umumkan di Indonesia, pada perusahaan Farmasi yang terdaftar di BEI. Metode analisis yang digunakan adalah Uji Beda Paired Sample T-Test. Populasi dalam penelitian ini adalah seluruh perusahaan Farmasi yang terdaftar di Bursa Efek Indonesia yakni sebanyak 12 Perusahaan. Sampel yang digunakan dalam penelitian ini adalah 11 perusahaan pada periode 2019-2021 yang terdiri dari Darya-Varia Laboratoria Tbk (DVLA), Indofarma Tbk (INAF), PT Kimia Farma Tbk (KAEF), Kalbe Farma Tbk (KLBF), Merck Tbk (MERK), PT Phapros Tbk (PEHA), Pyridam Farma Tbk (PYFA), PT Organon Pharma Indonesia Tbk (SCPI), PT Industri Jamu Dan Farmasi Sido Muncul Tbk (SIDO), Tempo Scan Pacific Tbk (TSPC), dan Millennium Pharmacon International Tbk (SDPC). Hasil Penelitian menemukan bahwa tidak terdapat perbedaan kinerja keuangan sebelum dan saat virus covid-19 pada perusahaan farmasi yang terdaftar di BEI ditinjau dari rasio likuiditas, rasio aktivitas, dan rasio profitabilitas. Berdasarkan hasil penelitian maka dapat disimpulkan tidak terdapat perbedaan kinerja keuangan sebelum dan saat pandemi virus covid-19. Kata Kunci: Likuiditas, Aktivitas, Profitabilitas, Kinerja Keuangan   
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信